Speaking at parliament, Chen was downbeat on the chances for finalising the agreement."At present there has been no further progress, and the opportunity for both to complete the contract is getting less and less," he added.Taiwan has a contract for 5 million of Moderna's COVID-19 shot, a messenger RNA (mRNA) vaccine that relies on similar technology as that used by the Pfizer-BioNTech one.
AdvertisementAdvertisementChen said that with the Moderna ones coming, as well as domestically made vaccines in development, there was less urgency to obtain the Pfizer-BioNTech one, though Taiwan would still like them if possible."We are still in communication with them," he added.
BioNTech did not immediately respond to a request for comment.BioNTech signed a deal with Chinese firm Shanghai Fosun Pharmaceutical Group to exclusively develop and commercialise COVID-19 vaccine products developed using its mRNA technology in mainland China, Hong Kong, Macau and Taiwan. In return Fosun agreed to pay up to US$85 million in licensing fees and invest US$50 million for a stake in the German firm. headtopics.com
AdvertisementBioNTech's development and distribution partner for the rest of the world is US firm Pfizer. Read more: CNA »